Media stories about Adamas Pharmaceuticals (NASDAQ:ADMS) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adamas Pharmaceuticals earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media coverage about the specialty pharmaceutical company an impact score of 44.9613456313235 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

ADMS has been the subject of a number of recent research reports. Cowen and Company reiterated an “outperform” rating and issued a $45.00 price target on shares of Adamas Pharmaceuticals in a research note on Sunday, May 28th. Mizuho reiterated a “buy” rating and issued a $26.00 price target on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 6th. Zacks Investment Research upgraded shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub downgraded shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Finally, Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Adamas Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $33.00.

Shares of Adamas Pharmaceuticals (ADMS) traded down 1.25% during mid-day trading on Monday, hitting $21.26. 782,297 shares of the stock traded hands. The stock has a 50-day moving average of $18.00 and a 200 day moving average of $17.19. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $22.58. The stock’s market cap is $478.65 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. During the same quarter last year, the business earned ($0.78) earnings per share. The business’s revenue for the quarter was down 90.9% compared to the same quarter last year. Equities analysts predict that Adamas Pharmaceuticals will post ($3.79) EPS for the current fiscal year.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of the firm’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total transaction of $6,490,400.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 29.00% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Adamas Pharmaceuticals (ADMS) Share Price” was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/18/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-adamas-pharmaceuticals-adms-share-price.html.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.